Iron Supplementation During Pregnancy - One Versus Two Ferrous Sulfate Capsules for Iron Deficient Pregnant Women
NCT ID: NCT02558725
Last Updated: 2015-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2015-04-30
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this trial the investigators sought to assess the efficacy of doubling the daily iron supplement dose in pregnant women with IDA.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion criteria were healthy pregnant women ages 18-42 with a singleton gestation and a diagnosis of IDA between 16-19 weeks. The investigators included only women with full access to medical computerized files. Exclusion criteria were: multiple pregnancies, hyperemesis gravidarum continuing past 20 weeks of gestation, Thalassemia, abnormal blood smears, vitamin D deficiency, mal-absorption disorders (inflammable bowel diseases; Crohn's, Ulcerative Colitis) and chronic diseases associated with anemia (i.e SLE). Vitamin B12 and blood smears were performed at the time of allocation. Additional inclusion criteria applied after allocation were: deterioration in hemoglobin levels mandating IV iron administration, more than 3 capsules missed at the 2 weeks check-up, diarrhea lasting more than 5 days, vomiting lasting more than 5 days less than 2 hours after supplement , administration of blood products during pregnancy, any use of multi-vitamin supplements containing iron, hospitalization periods greater than two weeks and a time period shorter than 15 weeks from allocation to delivery.
All participants diagnosed with IDA fulfilling the inclusion criteria were randomized by "Randomizer" (http://www.randomizer.org) to receive either one or two capsules of aktiferrin F (containing DL-Serine 129 mg; Iron (Ferrous Sulfate) 34 mg; Folic Acid 0.5 mg) or Foliferrin (containing DL-Serine 120 mg; Iron (Ferrous Sulfate) 34 mg; Folic Acid 0.5 mg). No cross-over was permitted between groups.
Participants were instructed to take one capsule at least 2 hours after consumption of dairy products or two capsules 12 hours apart at least 2 hours after consumption of dairy products. Validation of compliance to medical regimens was performed by a count of empty pill packages every two weeks during regular check-ups. All participants were monitored for weight, BP and urine dipstick measurements every 2-3 weeks until 34 weeks. Episodes of vomiting, constipation and diarrhea were recorded. Constipation was defined as fewer than three bowel movements a week or bowel movements consisting of hard, dry and small stool, making it painful or difficult to pass. Fetal BPP and estimated weight were performed every 2-3 weeks until 34 weeks of gestation. Fetal monitor was performed every two weeks from 34 weeks of gestation.
Laboratory follow up was performed by measurements of ferritin and hemoglobin levels at fixed time intervals during gestation: 15-20 weeks, 24 weeks, 35 weeks and also 6 weeks post-partum. All lab studies were performed in a single central laboratory.
The data extracted included demographic data (age, parity, chronic disease, weight and BMI at allocation and weight gain during the study period), obstetrical complications (GDM, preeclampsia, IUGR, preterm labor, preterm delivery, IUFD and blood product transfusion) and non obstetrical complications (diarrhea, thrombocytopenia, gastroenteritis, appendicitis, hypo/hyperthyroidism, pre-gestational diabetes) and newborn outcome (birth-weight and Apgar score and immediate post-partum complications). Any gastrointestinal symptoms, obstetrical complications or hospital admissions were reported in real time to the PI
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
one capsule of iron supplement
instructed to take one capsule at least 2 hours after consumption of dairy products
No interventions assigned to this group
two capsules of iron supplement
instructed to take two capsules of Aktiferrin F at least 2 hours after consumption of dairy products
two capsules of aktiferrin F
two capsules of Aktiferrin F or Foliferrin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
two capsules of aktiferrin F
two capsules of Aktiferrin F or Foliferrin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A diagnosis of iron deficiency anemia (defined as a hemoglobin concentration \<10.5 g/dL and ferritin levels \< 15 ng/ml) between 16-19 weeks
3. Full access to medical computerized files.
Exclusion Criteria
2. Thalassemia
3. Abnormal blood smears
4. Vitamin D deficiency
5. Mal-absorption disorders (inflammable bowel diseases; Crohn's, Ulcerative Colitis)
6. Chronic diseases associated with anemia (i.e SLE).
7. Deterioration in hemoglobin levels mandating IV iron administration
8. More than 3 capsules missed at the 2 weeks check-up
9. diarrhea lasting more than 5 days
10. Vomiting lasting more than 5 days less than 2 hours after supplement ingestion
11. Administration of blood products during pregnancy
12. Use of multi-vitamin supplements containing iron
13. Hospitalization periods greater than two weeks
14. A time period shorter than 15 weeks from allocation to delivery -
18 Years
42 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assuta Hospital Systems
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
maslovitz sharon
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon Maslovitz, Dr
Role: PRINCIPAL_INVESTIGATOR
Maccabi Healthcare Services, Israel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assuta Medical Center
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Shinar S, Skornick-Rapaport A, Maslovitz S. Iron supplementation in singleton pregnancy: Is there a benefit to doubling the dose of elemental iron in iron-deficient pregnant women? a randomized controlled trial. J Perinatol. 2017 Jul;37(7):782-786. doi: 10.1038/jp.2017.43. Epub 2017 Apr 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015057
Identifier Type: -
Identifier Source: org_study_id